Recently, eEF2 K has been actively investigated as a therapeutic target for breast cancer, and many eEF2 K inhibitors, such as NH125, TX- 1918, A- 484954, and fluoxetine, etc., have been developed. This evidence concerns the gene EEF2K and breast carcinoma.